Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 3
2009 1
2010 1
2012 2
2013 2
2014 1
2015 1
2017 5
2018 3
2019 6
2020 9
2021 12
2022 11
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML, Sweet KL, Emadi A, Ravandi F, Erba HP, Byrne M, Michaelis L, Topp MS, Vey N, Ciceri F, Carrabba MG, Paolini S, Huls GA, Jongen-Lavrencic M, Wermke M, Chevallier P, Gyan E, Récher C, Stiff PJ, Pettit KM, Löwenberg B, Church SE, Anderson E, Vadakekolathu J, Santaguida M, Rettig MP, Muth J, Curtis T, Fehr E, Guo K, Zhao J, Bakkacha O, Jacobs K, Tran K, Kaminker P, Kostova M, Bonvini E, Walter RB, Davidson-Moncada JK, Rutella S, DiPersio JF. Uy GL, et al. Blood. 2021 Feb 11;137(6):751-762. doi: 10.1182/blood.2020007732. Blood. 2021. PMID: 32929488 Free PMC article. Clinical Trial.
Determination of genetic relationship between environmental Escherichia coli with PFGE and investigation of IS element in bla(CTX-M) gene of these isolates.
Valizadeh S, Yousefi B, Abdolshahi A, Emadi A, Eslami M. Valizadeh S, et al. Microb Pathog. 2021 Oct;159:105154. doi: 10.1016/j.micpath.2021.105154. Epub 2021 Aug 19. Microb Pathog. 2021. PMID: 34419612
The bla(CTX-M) producing E. coli and IS element of this gene with phylogenetic typing were detected by PCR. ...The majority of isolates were resistant to cefotaxime and ceftazidime antibiotics and also phosphomycin antibiotic resistant were detected in 10% of isolates. CTX …
The bla(CTX-M) producing E. coli and IS element of this gene with phylogenetic typing were detected by PCR. ...The majority of isolat …
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Altman JK, Zuckerman T, Koprivnikar J, McCloskey J, Kota V, Keng M, Frankfurt O, Abaza Y, Bixby DL, Emadi A, Burch M, Bhatnagar B, Luger SM, Percival ME, Wolach O, Craig M, Ganzel C, Roboz G, Levi I, Gourevitch A, Flaishon L, Tessler S, Blumberg C, Gengrinovitch S, Ben Yakar R, Rowe JM. Altman JK, et al. Blood Adv. 2023 Dec 26;7(24):7494-7500. doi: 10.1182/bloodadvances.2023010943. Blood Adv. 2023. PMID: 37903324 Free PMC article. Clinical Trial.
Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.
Adige S, Lapidus RG, Carter-Cooper BA, Duffy A, Patzke C, Law JY, Baer MR, Ambulos NP, Zou Y, Bentzen SM, Emadi A. Adige S, et al. Cancer Chemother Pharmacol. 2019 Jun;83(6):1105-1112. doi: 10.1007/s00280-019-03825-2. Epub 2019 Apr 9. Cancer Chemother Pharmacol. 2019. PMID: 30968179 Free PMC article. Review.
In the treatment of acute myeloid leukemia (AML), the "7 + 3"-based strategy, combining cytarabine 100-200 mg/m(2) for 7 days with an anthracycline for 3 days, remains the standard of care for younger and medically fit patients. ...
In the treatment of acute myeloid leukemia (AML), the "7 + 3"-based strategy, combining cytarabine 100-200 mg/m(2) for 7 days with an …
Body fat and risk of all-cause mortality: a systematic review and dose-response meta-analysis of prospective cohort studies.
Jayedi A, Khan TA, Aune D, Emadi A, Shab-Bidar S. Jayedi A, et al. Int J Obes (Lond). 2022 Sep;46(9):1573-1581. doi: 10.1038/s41366-022-01165-5. Epub 2022 Jun 18. Int J Obes (Lond). 2022. PMID: 35717418 Review.
The HRs were 1.06 (95%CI: 1.01, 1.12; I(2) = 86%, n = 10) for a 5 kg increment in FM, 1.11 (95%CI: 1.06, 1.16; I(2) = 79%, n = 7) for a 2 kg/m(2) increment in FMI, and 1.17 (95%CI: 1.03, 1.33; I(2) = 72%, n = 8) and 0.81 (0.66, 0.99; I(2) = 59%, n = 6) for a 1-SD increment …
The HRs were 1.06 (95%CI: 1.01, 1.12; I(2) = 86%, n = 10) for a 5 kg increment in FM, 1.11 (95%CI: 1.06, 1.16; I(2) = 79%, n = 7) for a 2 kg …
Increased body mass index is a risk factor for acute promyelocytic leukemia.
Kashanian SM, Li AY, Mustafa Ali M, Sutherland ME, Duong VH, Hambley BC, Zacholski K, El Chaer F, Holtzman NG, Imran M, Patzke CL, Cornu J, Duffy A, Dezern AE, Gojo I, Norsworthy KJ, Levis MJ, Smith BD, Baer MR, Ghiaur G, Emadi A. Kashanian SM, et al. EJHaem. 2021 Feb;2(1):33-39. doi: 10.1002/jha2.163. Epub 2021 Jan 6. EJHaem. 2021. PMID: 33693438 Free PMC article.
RESULTS: Patients with APL had a significantly higher unadjusted mean and median BMI (32.5 kg/m(2) and 30.3 kg/m(2)) than those with AML (28.3 kg/m(2) and 27.1 kg/m(2)), ALL (29.3 kg/m(2) and 27.7 kg/m(2)), and others (29.3 kg/m(2) …
RESULTS: Patients with APL had a significantly higher unadjusted mean and median BMI (32.5 kg/m(2) and 30.3 kg/m(2)) than thos …
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, Mateus EF, Richez C, Santos MJ, Schmajuk G, Scirè CA, Sirotich E, Sparks JA, Sufka P, Thomas T, Trupin L, Wallace ZS, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann JS, Hyrich KL, Izadi Z, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson PC, Yazdany J, Machado PM; COVID-19 Global Rheumatology Alliance. Strangfeld A, et al. Ann Rheum Dis. 2021 Jul;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27. Ann Rheum Dis. 2021. PMID: 33504483 Free PMC article.
Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia.
Patzke CL, Duffy AP, Duong VH, El Chaer F, Trovato JA, Baer MR, Bentzen SM, Emadi A. Patzke CL, et al. J Clin Med. 2020 Feb 16;9(2):536. doi: 10.3390/jcm9020536. J Clin Med. 2020. PMID: 32079074 Free PMC article.
We present our institutional experience with using either CLAG-M or HAM-pegA, a novel regimen that includes pegaspargase. This is a retrospective comparison of 34 patients receiving CLAG-M and 10 receiving HAM-pegA as first salvage cytotoxic chemotherapy in the rela …
We present our institutional experience with using either CLAG-M or HAM-pegA, a novel regimen that includes pegaspargase. This is a r …
62 results